Gossamer Bio, Inc.
GOSS
$3.42
$0.4314.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -58.17% | -58.02% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -58.17% | -58.02% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -58.17% | -58.02% | -- | -- | -- |
| SG&A Expenses | 0.91% | -3.69% | -7.04% | -6.04% | -15.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.40% | 12.48% | 6.91% | 0.51% | -11.06% |
| Operating Income | -144.10% | -109.86% | 67.35% | 65.51% | 66.77% |
| Income Before Tax | -132.02% | -86.20% | 70.83% | 69.06% | 63.54% |
| Income Tax Expenses | -172.96% | -179.86% | -- | -- | -- |
| Earnings from Continuing Operations | -117.96% | -71.60% | 70.31% | 68.56% | 61.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.96% | -71.60% | 70.31% | 68.56% | 61.77% |
| EBIT | -144.10% | -109.86% | 67.35% | 65.51% | 66.77% |
| EBITDA | -147.92% | -113.03% | 67.43% | 65.67% | 67.00% |
| EPS Basic | -162.08% | -94.68% | 64.68% | 71.42% | 81.97% |
| Normalized Basic EPS | -211.38% | -144.94% | 52.98% | 62.97% | 83.22% |
| EPS Diluted | -162.01% | -94.74% | 64.78% | 71.50% | 81.99% |
| Normalized Diluted EPS | -199.13% | -136.99% | 51.81% | 62.09% | 82.54% |
| Average Basic Shares Outstanding | 0.55% | 4.23% | 22.52% | 48.68% | 89.27% |
| Average Diluted Shares Outstanding | -0.80% | 2.77% | 24.18% | 50.71% | 91.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |